Fibroblast Growth Factor-23 and Hypophosphatemia in Chronic Obstructive Pulmonary Disease Patients
| Autor: | Mohamed Y. Elsammak, Adel Attia, Moosa Suleman |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Fibroblast growth factor 23
medicine.medical_specialty COPD biology business.industry Biochemistry (medical) Clinical Biochemistry Serum albumin Pulmonary disease medicine.disease Control subjects Phosphate Gastroenterology chemistry.chemical_compound Disease severity chemistry Internal medicine medicine biology.protein business Hypophosphatemia |
| Zdroj: | Journal of Medical Biochemistry. 31:12-18 |
| ISSN: | 1452-8266 1452-8258 |
| DOI: | 10.2478/v10011-011-0031-5 |
| Popis: | Fibroblast Growth Factor-23 and Hypophosphatemia in Chronic Obstructive Pulmonary Disease PatientsImpaired serum phosphate levels may contribute to respiratory muscle weakness that further negatively impacts Chronic Obstructive Pulmonary Disease (COPD) patients. Recently, Fibroblast Growth Factor 23 (FGF-23) has been shown to play an important role in the regulation of body phosphate. The current study includes 2 groups: 70 COPD patients and 34 control subjects. Blood samples were taken for a panel of routine lab tests. FGF-23 was measured using a commercially available ELISA kit. Plasma FGF-23 levels were significantly higher in the patient group compared to the control group (P=0.000). Tubular maximum absorption of phosphate was significantly reduced in COPD patients compared to the control group (P=0.04). Plasma FGF-23 negatively correlated with FEV1 and serum albumin. Elevated plasma FGF-23 levels found in COPD patients correlated with disease severity and may represent an additional factor causing low serum phosphate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|